← All trials
NCT05981742
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2022
- Primary completion
- Mar 31, 2023
- Completion date
- Mar 31, 2023
- First posted
- Aug 8, 2023
- Last posted
- Aug 8, 2023
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaghdadLead sponsor
- Al-Mustafa University CollegeStudy chair
- University of BaghdadReponsible party - principal investigator
- Al-Mustafa University CollegeOfficial
- University of BaghdadSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.